Title: Pliant Therapeutics, Inc. (PLRX) 10K Annual Reports & 10Q SEC Filings
URL: https://last10k.com/sec-filings/plrx

HOME


LOGIN


PREMIUM


FREE TRIAL


SEC FILINGS


STOCK SCREENERS


EARNINGS


TRENDING


STOCKTWITS


INSIDER TRADING


SENTIMENT ANALYSIS


MANAGER PORTFOLIOS


LATE CORPORATE NEWS






				 



Pliant Therapeutics, Inc. (PLRX) SEC Filing 10-K Annual Report for the fiscal year ending Sunday, December 31, 2023


Home
SEC Filings
Pliant Therapeutics, Inc. (PLRX)
10-K Annual Report Tue Feb 27 2024






SEC Filings



 
PLRX Valuations





Intrinsic Value





Financial Stability





Financial Ratios





Insider Trades





Manager Portfolios





Notifications





 
PLRX Annual Reports
				  





10-K Annual Report February 2024


PDF

PDF


Select PDF Feature:
Include Exhibits
Highlight YoY Changes
Highlight Sentiment

10-K Only


Word
Excel
CSV


Table of Contents
Table of C
Special Note Regarding ForwardLooking Statements
Summary of Risks Associated With Our Business
Business
Risk Factors
Unresolved Staff Comments
ybersecurity
Properties
Legal Proceedings
Mine Safety Disclosures
Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Reserved
Managements Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
Exhibits and Financial Statement Schedules
Form 10K Summary








									10-K Annual Report March 2023																






									10-K Annual Report March 2022																






									10-K Annual Report March 2021																






PLRX Quarterly Reports
				  





									10-Q Quarterly Report August 2024																






									10-Q Quarterly Report May 2024																






									10-Q Quarterly Report November 2023																






									10-Q Quarterly Report August 2023																






									10-Q Quarterly Report May 2023																






									10-Q Quarterly Report November 2022																






									10-Q Quarterly Report August 2022																






									10-Q Quarterly Report May 2022																






									10-Q Quarterly Report November 2021																






									10-Q Quarterly Report August 2021																






PLRX Corporate News
				  





									Bylaw ChangeFinancial Exhibit																	September 2024







									Earnings ReleaseFinancial Exhibit																	August 2024







									Financial ExhibitOther Events																	July 2024







									Event for OfficersVote of Security Holders																	June 2024







									Financial ExhibitOther Events																	May 2024







									Earnings ReleaseFinancial Exhibit																	May 2024







									Financial ExhibitNew AgreementNew Financial ObligationOther Events																	March 2024







									Earnings ReleaseFinancial Exhibit																	February 2024







									Financial ExhibitOther Events																	February 2024







									Earnings ReleaseFinancial Exhibit																	November 2023







PLRX Registration of Securities
				  





									S-1 Registration of Securities May 2020																












Last10K.com | 10-K Annual Report Tue Feb 27 2024






Pliant Therapeutics, Inc.


													CIK: 1746473
																										Ticker: PLRX




Earnings Press Release
 10-K Annual Report
 10-K YoY Changes
 Annual Proxy




Pliant Therapeutics, Inc.

HISTORY
TOOLS


CIK: 1746473
Ticker: PLRX




Exhibit 99.1Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial ResultsPositive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment continues in BEACON-IPF, a Phase 2b trial in patients with IPFSOUTH SAN FRANCISCO, CA., February 27, 2024 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2023 financial results.“The progress made by our teams during the fourth quarter of 2023 position us well for executing upon our 2024 milestones including the recent positive data from the INTEGRIS-PSC trial that support the late-stage development of bexotegrast in this important indication," said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics. “In 2024, our focus will be on the advancement the BEACON-IPF late-stage program, gathering clarity on next steps for a late-stage PSC program and providing updates to our early-stage portfolio including from our oncology and muscular dystrophy programs."  Fourth Quarter and Recent HighlightsBexotegrast Highlights•Positive safety and efficacy data from 320 mg dose cohort of INTEGRIS-PSC Phase 2a trial in patients with primary sclerosing cholangitis (PSC). At a once-daily dose of 320 mg, bexotegrast was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events. At the 320 mg dose, bexotegrast reduced both Enhanced Liver Fibrosis (ELF) scores and PRO-C3 levels and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12. Twenty-four-week data from the 320 mg dose group is expected in mid-2024.•Enrollment continues in BEACON-IPF, a Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). BEACON-IPF is a 52-week, multinational, randomized, dose-ranging, double-blind, placebo-controlled trial evaluating bexotegrast at once-daily doses of 160 mg or 320 mg. BEACON-IPF is expected to enroll approximately 270 patients with IPF.  Pipeline Programs•Phase 1 trial of PLN-101095 in solid tumors is enrolling. This is a Phase 1 open label trial of PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins designed to block TGF-β activation in the tumor microenvironment. The trial is currently dosing the third of five planned dose cohorts in a Phase 1 open label dose-escalation trial of PLN-101095 as monotherapy and in combination with pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. Preliminary data is expected in late 2024. •Muscular dystrophy program on track for regulatory filing in the first quarter of 2024. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin α7β1. Filing for first-in-human clinical studies in Duchenne muscular dystrophy (DMD) is expected in the first quarter of 2024.The following information was filed by Pliant Therapeutics, Inc. (PLRX) on Tuesday, February 27, 2024 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release. 

Please wait while we load the requested 10-K report or click the link below:https://last10k.com/sec-filings/report/1746473/000174647324000043/plrx-20231231.htm


View differences made from one year to another to evaluate Pliant Therapeutics, Inc.'s financial trajectory





Sample 10-K Year-over-Year (YoY) Comparison



Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pliant Therapeutics, Inc..

Continue







Assess how Pliant Therapeutics, Inc.'s management team is paid from their Annual Proxy





Screenshot example of actual Proxy Statement




Pliant Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors


Continue














SEC Filing Tools




 Sentiment
 Sections
 Exhibits
 Stats


 



 Rating					
Learn More










Filter Sentiment:



All






Positive




Negative





Filter Category:




All





Financial







Revenue






Legal






Other






Filter Subcategory:




All






Expense






Product






Geography






Shares






Debt






Income






Other







 Inside Pliant Therapeutics, Inc.'s 10-K Annual Report:


 Financial - Expense   Highlight
•$0.3 million decrease in depreciation of lab equipment and costs of equipment and supplies; and



 Other - Other   Highlight
These statements are based upon information available to us as of the date of this Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate we have conducted exhaustive inquiry into, or review of, all potentially available relevant information.

 Financial - Expense   Highlight
We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will increase in connection with our ongoing activities, as we: •perform research and development activities to identify and develop product candidates;

 Financial - Expense   Highlight
We expect general and administrative expenses to increase for the foreseeable future as does the size of our administrative function to support the growth of our business.

 Revenue - Product   Highlight
Revenue decreased by $8.1 million due to decreased research and development services resulting from the termination of the Novartis Agreement.

 Other - Other
Performance obligations are promised goods...Read more

 Other - Other
In addition, statements that “we...Read more

 Other - Other
We have based these estimates...Read more

 Revenue - Geography
•the outcome, timing and cost...Read more

 Financial - Expense
The process of conducting the...Read more

 Other - Other
The Novartis Agreement was for...Read more

 Revenue - Product
We recognize revenue when our...Read more

 Financial - Expense
The increase in cash used...Read more

 Other - Other
We estimate the transaction price...Read more

 Other - Other
At the 320 mg dose,...Read more

 Other - Other
Our fourth program to date,...Read more

 Other - Other
The increase in cash provided...Read more

 Legal - Other
•the cost of filing, prosecuting,...Read more

 Financial - Expense
As a result, we are...Read more

 Financial - Shares
In July 2022, we completed...Read more

 Financial - Shares
In January 2023, we completed...Read more

 Other - Other
We enter into contracts in...Read more

 Other - Other
Further, our operating plan may...Read more

 Other - Other
We are a late stage...Read more

 Financial - Expense
We record accrued expenses for...Read more

 Other - Other
These statements are inherently uncertain...Read more

 Financial - Debt
Our cash, cash equivalents and...Read more

 Revenue - Product
•the cost of establishing sales,...Read more

 Other - Other
Certain variable consideration is allocated...Read more

 Financial - Expense
Additionally, although external third-party costs...Read more

 Other - Other
The promised goods or services...Read more

 Revenue - Product
If we raise additional capital...Read more

 Other - Other
•expand our operational, financial and...Read more

 Financial - Expense
We expense all research and...Read more

 Financial - Expense
We expect our research and...Read more

 Financial - Shares
We have not issued any...Read more

 Revenue - Product
Our revenue to date is...Read more

 Other - Other
We announced positive interim data...Read more

 Other - Other
In assessing whether promised goods...Read more

 Financial - Expense
We do not allocate our...Read more

 Financial - Shares
During the third quarter of...Read more

 Other - Other
We estimate the amount of...Read more

 Revenue - Product
Our operations have been financed...Read more

 Other - Other
We only apply the five-step...Read more

 Other - Other
•Positive safety and efficacy data...Read more

 Other - Other
Management’s Discussion and Analysis of...Read more

 Revenue - Product
Following termination of the Novartis...Read more

 Financial - Expense
Any payments made in advance...Read more

 Financial - Expense
The preparation of these financial...Read more

 Financial - Expense
•expenses incurred under agreements with...Read more

 Financial - Expense
•$23.2 million increase in clinical...Read more

 Financial - Expense
Interest expense increased $0.5 million...Read more

 Other - Other
At the inception of each...Read more

 Other - Other
Our initial focus is on...Read more

 Financial - Expense
We utilize a cost-based input...Read more

 Other - Other
We have developed PLN-1474, a...Read more

 Other - Other
In January 2023, we received...Read more

 Other - Other
If we are unable to...Read more

 Other - Other
Under the terms of the...Read more

 Other - Other
Further, our operating plan may...Read more

 Financial - Shares
We may seek to raise...Read more

 Financial - Debt
If we raise additional capital...Read more

 Financial - Expense
We utilize key assumptions to...Read more

 Financial - Shares
The shares were offered at...Read more

 Other - Other
Options are considered to be...Read more

 Other - Other
At December 31, 2023, we...Read more

 Financial - Expense
We record the estimated costs...Read more

 Revenue - Product
We recognize revenue at the...Read more

 Financial - Shares
The shares were offered at...Read more

 Financial - Expense
For the periods presented, we...Read more

 Other - Other
We expect to file with...Read more

 Financial - Expense
•the initiation, progress, timing, costs...Read more

 Revenue - Product
If it is probable that...Read more

 Revenue - Product
We have not generated any...Read more

 Other - Other
As part of a broad...Read more

 Other - Other
We must develop assumptions that...Read more

 Other - Other
•whether we enter into any...Read more

 Other - Other
We utilize either the most...Read more

 Other - Other
Our estimates are based on...Read more

 Other - Other
Our wholly-owned lead product candidate,...Read more

 Other - Other
In February 2023, Novartis issued...Read more

 Revenue - Product
In addition, if we obtain...Read more

 Other - Other
Actual results may differ from...Read more

 Other - Other
•Enrollment continues in BEACON-IPF, a...Read more

 Other - Other
•require the manufacture of supplies...Read more

 Other - Other
The determination as to whether...Read more

 Financial - Expense
Our interest expense is derived...Read more

 Financial - Expense
Our accrued expenses and prepaid...Read more

 Other - Other
We make significant judgments and...Read more

 Revenue - Product
As of December 31, 2023, all...Read more

 Other - Other
As of December 31, 2023, we...Read more

 Financial - Expense
We record accrued expenses for...Read more

 Other - Other
As of December 31, 2023, we...Read more

 Financial - Expense
Our general and administrative expenses...Read more

 Other - Other
At December 31, 2023, $25.0...Read more

 Other - Other
We evaluate every contract to...Read more

 Financial - Expense
•employee-related expenses, which include salaries,...Read more

 Other - Other
This is a Phase 1...Read more

 Financial - Expense
•the cost and timing of...Read more

 Financial - Expense
Our primary use of cash...Read more

 Other - Other
We are currently conducting BEACON-IPF,...Read more

 Financial - Expense
•the timelines of our clinical...Read more

 Financial - Expense
•costs associated with the manufacture...Read more

 Other - Other
Filing for first-in-human clinical studies...Read more

 Revenue - Product
In March 2023, we filed...Read more

 Other - Other
PLN-1474 was licensed to Novartis...Read more

 Other - Other
The trial is currently dosing...Read more

 Financial - Expense
•facilities and other allocated expenses,...Read more

 Other - Other
We are currently dosing the...Read more

 Financial - Expense
•$16.3 million increase in employee-related...Read more

 Revenue - Product
All contingent future payments, which...Read more

 Other - Other
The decrease in cash used...Read more

 Other - Other
BEACON-IPF is a 52-week, multinational,...Read more

 Other - Other
•seek regulatory approvals for any...Read more

 Other - Other
•Muscular dystrophy program on track...Read more

 Financial - Expense
We believe that our existing...Read more

 Other - Other
Upon closing of the Oxford...Read more

 Other - Other
PLN-101325 is a monoclonal antibody...Read more

 Other - Other
PLN-101325 is a monoclonal antibody...Read more

 Financial - Income
Our interest and other income...Read more

 Financial - Expense
Our research and development expenses...Read more

 Other - Other
We have applied our deep...Read more

 Other - Other
At a once-daily dose of...Read more

 Financial - Expense
Cash used to fund operating...Read more

 Financial - Expense
•the cost and timing of...Read more

 Financial - Expense
If we under estimate or...Read more



 
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report





Audit Information





Cover





Balance Sheets





Balance Sheets (Parenthetical)





Statements Of Cash Flows





Statements Of Operations And Comprehensive Gain (Loss)





Statements Of Stockholders' Equity





Accrued Liabilities





Accrued Liabilities (Tables)





Accrued Liabilities - Summary Of Accrued Liabilities (Details)





Commitments And Contingencies





Commitments And Contingencies (Details)





Common Stock





Common Stock (Tables)





Common Stock - Narrative (Details)





Common Stock - Summary Of Shares Reserved For Future Issuance (Details)





Debt





Debt (Tables)





Debt - Narrative (Details)





Debt - Summary Of Maturities Of Long-Term Debt (Details)





Defined Contribution Plan





Defined Contribution Plan (Details)





Financial Instruments





Financial Instruments (Tables)





Financial Instruments - Narrative (Details)





Financial Instruments - Summary Of Cash And Cash Equivalents, Money Market Funds And Short-Term Investments By Significant Investment Category (Details)





Financial Instruments - Summary Of Remaining Contractual Maturities Of Company's Short-Term Investments (Details)





Income Taxes





Income Taxes (Tables)





Income Taxes - Summary Of Changes In Valuation Allowance For Deferred Tax Assets (Details)





Income Taxes - Summary Of Deferred Tax Assets And Liabilities (Details)





Income Taxes - Summary Of Net Operating Losses And Tax Credit Carry Forwards (Details)





Income Taxes - Summary Of Reconciliation Of U.S. Federal Statutory Income Tax Rate To Company???S Effective Income Tax Rate (Details)





Income Taxes - Summary Of Reconciliation Of Unrecognized Tax Benefits (Details)





Income Taxes -Narrative (Details)





Insider Trading Arrangements





Leases





Leases (Tables)





Leases - Narrative (Details)





Leases - Summary Of Operating And Variable Lease Cost (Details)





Leases - Summary Of Operating Lease Liability (Details)





Leases - Summary Of Weighted-Average Remaining Lease Terms And Discount Rates (Details)





Net Loss Per Share Attributable To Common Stockholders





Net Loss Per Share Attributable To Common Stockholders (Tables)





Net Loss Per Share Attributable To Common Stockholders - Summary Of Potentially Dilutive Securities Excluded From Computation Of Diluted Net Loss Per Share (Details)





Novartis Collaboration And License Agreement (The "Novartis Agreement")





Novartis Collaboration And License Agreement (The "Novartis Agreement") - Narrative (Details)





Organization And Description Of Business





Organization And Description Of Business (Details)





Pay Vs Performance Disclosure





Preferred Stock





Preferred Stock (Details)





Prepaid Expenses And Other Current Assets





Prepaid Expenses And Other Current Assets (Details)





Prepaid Expenses And Other Current Assets (Tables)





Property And Equipment, Net





Property And Equipment, Net (Tables)





Property And Equipment, Net - Narrative (Details)





Property And Equipment, Net - Summary Of Property And Equipment Net (Details)





Related Party Transactions





Related Party Transactions - (Details)





Stock-Based Compensation





Stock-Based Compensation (Tables)





Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Summary Of Black-Scholes Option Pricing Model To Estimate Stock-Based Compensation Expense For 2020 Employee Stock Purchase Plan (Details)





Stock-Based Compensation - 2020 Employee Stock Purchase Plan Narrative (Details)





Stock-Based Compensation - Equity Incentive Plan - Narrative (Details)





Stock-Based Compensation - Incentive Stock Options And Nonqualified Stock Options - Narrative (Details)





Stock-Based Compensation - Restricted Stock Units - Narrative (Details)





Stock-Based Compensation - Restricted Stock Units And Performance-Based Restricted Stock Units - Narrative (Details)





Stock-Based Compensation - Summary Of Black-Scholes Option Pricing Model To Estimate Stock-Based Compensation Expense For Stock Option Awards (Details)





Stock-Based Compensation - Summary Of Classification Of Stock-Based Compensation Expense (Details)





Stock-Based Compensation - Summary Of Option Activity Under The 2015 Plan And 2020 Plan (Details)





Stock-Based Compensation - Summary Of Outstanding Psus Associated With The Tsr Goal (Details)





Stock-Based Compensation - Summary Of Restricted Stock Activity (Details)





Stock-Based Compensation - Summary Of Tsr Psu Valuation Assumptions (Details)





Summary Of Significant Accounting Policies





Summary Of Significant Accounting Policies (Policies)





Summary Of Significant Accounting Policies (Tables)





Summary Of Significant Accounting Policies - Narrative (Details)





Summary Of Significant Accounting Policies - Summary Of Useful Lives Of Property And Equipment (Details)




 
Material Contracts, Statements, Certifications & more
Pliant Therapeutics, Inc. provided additional information to their SEC Filing as exhibits





Exhibit 10.17: Material Contract





Exhibit 23.1: Consents Of Experts And Counsel





Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification





Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification





Exhibit 32.1: Section 1350 Certification





Exhibit 97: Ex-97Clawbackpolicy






Ticker: PLRX CIK: 1746473
Form Type: 10-K Annual Report
Accession Number: 0001746473-24-000043
Submitted to the SEC: Tue Feb 27 2024 4:14:06 PM EST
Accepted by the SEC: Tue Feb 27 2024
Period:  Sunday, December 31, 2023
Industry: Pharmaceutical Preparations						
External Resources:
 Stock Quote
 Social Media
 SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/plrx/0001746473-24-000043.htm








About 
											Contact 
											Help 
											API 
											Privacy 
											Terms 
									


© 2012 - 2024 Last10K.com All Rights Reserved









×
You're Signed Out
Sign in for the full experience


Sign in
Join Now








Intrinsic Value Calculator








Screenshot of intrinsic value for AT&T (2019)




Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not
Continue












Never Miss A New SEC Filing Again








Screenshot taken from Gmail for a new 10-K Annual Report




Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news
Continue












We Highlighted This SEC Filing For You








Screenshot taken from Wynn's 2018 10-K Annual Report




Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q
Continue












Widen Your SEC Filing Reading Experience








Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report




Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view
Continue












Uncover Actionable Information Inside SEC Filings








Screenshot taken from Lumber Liquidators 10-K Annual Report




Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q
Continue












Adobe PDF, Microsoft Word, Excel and CSV Downloads








Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats




Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis
Continue












Adobe PDF, Microsoft Word, Excel and CSV Downloads








Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats




Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis
Continue












Financial Stability Report








Screenshot of financial stability report for Coco-Cola (2019)




Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity
Continue












Get a Better Picture of a Company's Performance








Available Financial Ratios




Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years
Continue












See when company executives buy or sell their own stock








Screenshot taken from Euronet (EEFT)




Last10K.com Member Feature

Use our calculated cost dollar values to discover when and how much registered owners BUY, SELL or excercise their company stock OPTIONS aggregated from Form 4 Insider Transactions SEC Filings
Continue












See how institutional managers trade a stock








Screenshot taken from General Motors (GM)




Last10K.com Member Feature

View which hedge funds, pension / retirement funds, endowments, banks and insurance companies have increased or decreased their positions in a particular stock. Includes Ownership Percent, Buy versus Sell comparison, Put-Call ratio and more
Continue












FREE Financial Statements








Screenshot of actual balance sheet from company 10-K Annual Report




Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports
Continue for FREE












SEC Filing Exhibit
 PDF Download



Loading SEC Filing Exhibit...








SEC Filing Financial Summary
 PDF Download
 Excel Download



Loading SEC Filing Financial Summary...

